InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,626.02
(
0.54%
)
US TECH 100
18,986.40
(
0.30%
)
Dow Jones
41,393.78
(
0.72%
)
Brent Oil
71.83
(
0.00%
)
Bitcoin
60,175.33
(
0.28%
)
Post# of 4978934
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

RyNo_23

Send PM Follow Ignore
Followers 184
Posts 3751
Boards Moderated 1
Alias Born 04/22/2011

RyNo_23

Re: None

Wednesday, 04/28/2021 11:45:44 AM

Wednesday, April 28, 2021 11:45:44 AM

Post# of 4978934
New Investor presentation!

https://genebiotherapeutics.com/wp-content/uploads/2021/04/Gene-Biotherapeutics-Investor-Presentation.pdf

Generx [Ad5FGF-4] will initially be focused on refractory angina, which represents a significant potentially unmet medical need for ~1.2 million U.S. patients with coronary artery disease, representing a potential addressable market of > $14.0 billion (assuming $8,000 - $12,000 pricing range). We believe FDA approval of Generx would be high profile and garner significant worldwide attention.



$CRXM

Semper Fidelis

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up